Impact of the extent of extraprostatic extension defined by Epstein's method in patients with negative surgical margins and negative lymph node invasion
- PMID: 27401033
- DOI: 10.1038/pcan.2016.24
Impact of the extent of extraprostatic extension defined by Epstein's method in patients with negative surgical margins and negative lymph node invasion
Abstract
Background: To assess the impact of the degree of extraprostatic extension (EPE) on biochemical recurrence (BCR) and utility of the original Epstein's criteria to define EPE in a cohort of pT3aN0 without positive surgical margin (PSM).
Methods: A two-center retrospective analysis was performed on data from 490 pT3aN0 patients who underwent radical prostatectomy between 2000 and 2012. Patients with neoadjuvant and/or adjuvant therapy, detectable PSA and PSM were excluded. Our pathologists used Epstein's criteria to report the degree of EPE. When pathology reports did not reflect the terms 'focal' or 'established' (non-focal), slides were analyzed by a single genitourinary pathologist for final evaluation. The end point was defined by BCR.
Results: Selection criteria yielded 247 patients. Mean follow-up was 56.3±4.6 months; mean age at surgery was 62.5 years. Sixty-one (24.7%) patients experienced BCR during follow-up. Patients with focal extension had a 5-year recurrence-free survival of 89% versus 80% for those with non-focal extension (P=0.0018). In multivariate analysis, both pathologic Gleason score (hazard ratio 2.5; 95% confidence interval 1.4-4.5; P=0.002) and the extent of EPE (hazard ratio 1.8; 95% confidence interval 1.1-3.5; P=0.029) were significant predictors of BCR.
Conclusions: The extent of EPE is an independent predictor of BCR in pT3aN0 prostate cancer without PSM. This study reinforces the utility of the subjective Epstein approach already adopted by most pathologists for quantification of the extent of EPE.
Similar articles
-
Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy.Histopathology. 2011 Oct;59(4):692-702. doi: 10.1111/j.1365-2559.2011.03986.x. Histopathology. 2011. PMID: 22014050
-
The relationship between the extent of extraprostatic extension and survival following radical prostatectomy.Eur Urol. 2015 Feb;67(2):342-6. doi: 10.1016/j.eururo.2014.06.015. Epub 2014 Jun 23. Eur Urol. 2015. PMID: 24968968
-
Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?BJU Int. 2015 Sep;116(3):343-50. doi: 10.1111/bju.12911. Epub 2014 Dec 15. BJU Int. 2015. PMID: 25138271
-
Risk of Biochemical Recurrence in Patients With Grade Group 1 Prostate Cancer With Extraprostatic Extension Treated With Radical Prostatectomy.J Urol. 2024 Mar;211(3):407-414. doi: 10.1097/JU.0000000000003825. Epub 2023 Dec 18. J Urol. 2024. PMID: 38109699 Review.
-
Is Extraprostatic Extension of Cancer Predictable? A Review of Predictive Tools and an External Validation Based on a Large and a Single Center Cohort of Prostate Cancer Patients.Urology. 2019 Jul;129:8-20. doi: 10.1016/j.urology.2019.03.019. Epub 2019 Mar 28. Urology. 2019. PMID: 30928608 Review.
Cited by
-
Digital versus light microscopy assessment of extraprostatic extension in radical prostatectomy samples.Virchows Arch. 2019 Dec;475(6):735-744. doi: 10.1007/s00428-019-02666-x. Epub 2019 Oct 7. Virchows Arch. 2019. PMID: 31588959
-
Impact of United States Preventive Services Task Force recommendations on prostate biopsy characteristics and disease presentation at a tertiary-care medical center.Prostate Int. 2018 Sep;6(3):110-114. doi: 10.1016/j.prnil.2018.03.001. Epub 2018 Mar 9. Prostate Int. 2018. PMID: 30140661 Free PMC article.
-
Biochemical recurrence after radical prostatectomy: what does it mean?Int Braz J Urol. 2018 Jan-Feb;44(1):14-21. doi: 10.1590/S1677-5538.IBJU.2016.0656. Int Braz J Urol. 2018. PMID: 29039897 Free PMC article. Review.
-
Prediction of extraprostatic extension on multi-parametric magnetic resonance imaging in patients with anterior prostate cancer.Eur Radiol. 2020 Jan;30(1):26-37. doi: 10.1007/s00330-019-06340-3. Epub 2019 Aug 5. Eur Radiol. 2020. PMID: 31385046
-
Differences in the expression of the phosphatase PTP-1B in patients with localized prostate cancer with and without adverse pathological features.Front Oncol. 2024 Apr 19;14:1334845. doi: 10.3389/fonc.2024.1334845. eCollection 2024. Front Oncol. 2024. PMID: 38706600 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous